Showing results (71-80 of 118) with videos related to

Sort By:
Pageof 12
Oncotarget|December 30, 2017
Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitorsSimon Baldacci, Julien Mazieres, Pascale Tomasini, et al.
Therapeutic Advances in Medical Oncology|May 5, 2021
Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus "at progression" cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasisIsabelle Monnet, Alain Vergnenègre, Gilles Robinet, et al.
Plos One|September 14, 2023
Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study)Karen Leroy, Clarisse Audigier Valette, Jérôme Alexandre, et al.
Lung Cancer (Amsterdam, Netherlands)|July 2, 2023
VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trialGuénaëlle Levallet, Fatéméh Dubois, Nicolas Elie, et al.
The European Respiratory Journal|September 19, 2015
Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504Jacques Cadranel, Radj Gervais, Patrick Merle, et al.
British Journal of Cancer|February 12, 2019
MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trialElodie Maille, Solenn Brosseau, Vincent Hanoux, et al.
Clinical Lung Cancer|July 8, 2019
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS CohortSolenn Brosseau, Claire Danel, Arnaud Scherpereel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2019
Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III TrialGuillaume Eberst, Amélie Anota, Arnaud Scherpereel, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutationJean Bernard Auliac, Maurice Pérol, David Planchard, et al.
Clinical Lung Cancer|September 14, 2025
Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World AnalysisAntoine Bronstein, Hubert Curcio, Isabelle Monnet, et al.
Pageof 12